Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Canaccord Genuity analyst Kyle Mikson CFA has maintained their neutral stance on ILMN stock, giving a Hold rating today. Geoff Meacham has given his Hold rating due to a combination of factors ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) yesterday and set a price target of $242.00. The company’s shares closed last Friday at $104.38.

Illumina operates in the genetic and genomic analysis sector, providing products and services for research and clinical environments. The company's strategic priorities include achieving top-line ...

The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing ...